Terms: = Liver cancer AND HOXD13, SPD, 3239, P35453, HOX4I
57 results:
1. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
[TBL] [Abstract] [Full Text] [Related]
2. [Association of circulating levels of soluble PD-1, PD-1 gene polymorphisms with HBV infection and HBV infection-associated hepatocellular carcinoma].
Ma Y; Hao YQ; Bi LQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jun; 57(6):863-867. PubMed ID: 37357205
[No Abstract] [Full Text] [Related]
3. Soluble Programmed Cell Death Ligand-1 (spd-L1) Levels in Various cancer Types and Normal Populations.
Lee SH; Park HJ; Moon JY; Kim YT; Lee KR; Kwak MJ; Kim YJ
Clin Lab; 2023 Apr; 69(4):. PubMed ID: 37057933
[TBL] [Abstract] [Full Text] [Related]
4. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (spd-L1) in cancers.
Sun J; Hu S; Li X
Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
[TBL] [Abstract] [Full Text] [Related]
5. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
Wei H; Mao Y; Zhang H; Wu F; Zhang Y
Immunol Invest; 2023 Apr; 52(3):343-363. PubMed ID: 36762677
[TBL] [Abstract] [Full Text] [Related]
6. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
Chen L; Liu S; Adah D; Sun Q; Liang Z; Ho M; Sun B
Immunology; 2023 Jun; 169(2):204-218. PubMed ID: 36640111
[TBL] [Abstract] [Full Text] [Related]
7. An automated, rapid fluorescent immunoassay to quantify serum soluble programmed death-1 (PD-1) protein using testing-on-a-probe biosensors.
Zhang J; Chen L; Xu Q; Tao Y; Pan J; Guo J; Su J; Xie H; Chen Y
Clin Chem Lab Med; 2022 Jun; 60(7):1073-1080. PubMed ID: 35535427
[TBL] [Abstract] [Full Text] [Related]
8. Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B.
Chu YJ; Jeng WJ; Pan MH; Hu HH; Luo WS; Su CY; Chiang CT; Jen CL; Chen CJ; Yang HI
J Gastroenterol; 2022 Jun; 57(6):423-432. PubMed ID: 35459967
[TBL] [Abstract] [Full Text] [Related]
9. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients.
Xiaochen M; Xiangyang S; Fubo X; Wencheng J; Qingliang W; Yang X; Caixia L; Kai Z
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e515-e523. PubMed ID: 35289092
[TBL] [Abstract] [Full Text] [Related]
10. Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.
Kozuka R; Enomoto M; Dong MP; Hai H; Thuy LTT; Odagiri N; Yoshida K; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Tamori A; Kawada N
Sci Rep; 2022 Jan; 12(1):105. PubMed ID: 34996935
[TBL] [Abstract] [Full Text] [Related]
11. Circulating level of spd-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression.
Huyen PTM; Dung DTN; Weiß PJ; Hoan PQ; Giang DP; Uyen NT; Van Tuan N; Trung NT; Velavan TP; Song LH; Hoan NX
Int J Infect Dis; 2022 Feb; 115():229-236. PubMed ID: 34910956
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of soluble programmed cell death-1 (spd-1) and soluble programmed cell death ligand-1 (spd-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
[TBL] [Abstract] [Full Text] [Related]
13. Association of PD-L1 gene polymorphisms and circulating spd-L1 levels with HBV infection susceptibility and related liver disease progression.
Xuan Hoan N; Thi Minh Huyen P; Dinh Tung B; Phuong Giang D; Tat Trung N; Tien Sy B; Thi Tuan N; Thi Ngoc Dung D; Reddy Pallerla S; Velavan TP; Hong Bang M; Huu Song L
Gene; 2022 Jan; 806():145935. PubMed ID: 34478821
[TBL] [Abstract] [Full Text] [Related]
14. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract] [Full Text] [Related]
15. Nanobubbles Containing spd-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice.
Tan Y; Yang S; Ma Y; Li J; Xie Q; Liu C; Zhao Y
Int J Nanomedicine; 2021; 16():3241-3254. PubMed ID: 34007176
[TBL] [Abstract] [Full Text] [Related]
16. A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent.
Ma J; Li L; Yue K; Zhang Z; Su S; Chen Y; Yu L; Zhang P; Ma R; Li Y; Ma Y; Jia H; Wang C; Wang J; Xie S
Eur J Med Chem; 2021 Oct; 221():113469. PubMed ID: 33965862
[TBL] [Abstract] [Full Text] [Related]
17. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma.
Na BG; Kim YK; Hwang S; Lee KJ; Park GC; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yang H; Yoon YI; Tak E; Park YH; Lee SG
Medicine (Baltimore); 2021 Apr; 100(17):e25640. PubMed ID: 33907121
[TBL] [Abstract] [Full Text] [Related]
18. AMD1 upregulates hepatocellular carcinoma cells stemness by FTO mediated mRNA demethylation.
Bian X; Shi D; Xing K; Zhou H; Lu L; Yu D; Wu W
Clin Transl Med; 2021 Mar; 11(3):e352. PubMed ID: 33783988
[TBL] [Abstract] [Full Text] [Related]
19. Serum levels of soluble programmed death-ligand 1 (spd-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
[TBL] [Abstract] [Full Text] [Related]
20. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
[TBL] [Abstract] [Full Text] [Related]
[Next]
